Salarius Pharmaceuticals Email Format

Pharmaceutical ManufacturingTexas, United States2-10 Employees

Salarius Pharmaceuticals is a small clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing cancer therapies for patients with limited treatment options. Its portfolio centers on seclidemstat, a reversible LSD1 inhibitor being studied for pediatric cancers and sarcomas, including Ewing-related tumors, and SP-3164, an oral targeted protein degrader. Seclidemstat is in a Phase 1/2 trial for relapsed or refractory Ewing sarcoma and related sarcomas, and has FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease for this indication. The company is also pursuing seclidemstat in other cancers with high unmet medical needs and has initiated a second Phase 1/2 study in hematologic cancers led by MD Anderson.

Sign up for free to view info

Company overview Employee directory